Caris Life Sciences (CAI) EBT (2024 - 2026)

Caris Life Sciences' EBT history runs 3 years deep, the most recent figure standing at -$644000.0 for Q1 2026.

• In Q1 2026, EBT rose 99.37% year-over-year to -$644000.0; the TTM figure through Mar 2026 stood at $33.8 million (up 112.38% YoY), while the FY2025 annual figure was -$68.1 million, up 75.85% from the prior year.
• EBT for Q1 2026 stood at -$644000.0, down from $82.0 million in the prior quarter.
• The five-year high for EBT was $82.0 million in Q4 2025, with the low at -$102.6 million in Q1 2025.
• The 3-year median for EBT is -$51.6 million (2024), against an average of -$29.9 million.
• Peak annual rise in EBT reached 321.82% in 2025, while the deepest fall reached 8.47% in 2025.
• Caris Life Sciences' EBT stood at -$36.9 million in 2024, then surged by 321.82% to $82.0 million in 2025, then slumped by 100.79% to -$644000.0 in 2026.
• Business Quant data shows CAI's EBT at -$644000.0 in Q1 2026, $82.0 million in Q4 2025, and $24.3 million in Q3 2025.